Christopher Conway Appointed CEO of Bio X Cell

Christopher Conway has been named CEO of Bio X Cell, LLC, a manufacturer of monoclonal antibodies for preclinical in vivo research. Conway has vast experience in small molecule and biologics drug research. He was Curia's former President of R&D. Since his 2008 arrival at Curia, he has occupied a number of commercial leadership positions. Conway was appointed because of his solid background in business and the industry, as well as because he respects and understands the ethos and goals of Bio X Cell, which are to foster scientific innovation and discovery. In November 2023, Klaus Lubbe, the founder of the firm, sold Windjammer Capital Investors the bulk of his shares in BXC. He is still actively involved in new product development as a minority shareholder and board member.